2. Search Result
Search Result
Results for "

Pulmonary edema

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17417
    Naloxone hydrochloride
    5+ Cited Publications

    		 Opioid Receptor Neurological Disease Cancer
    Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .
    Naloxone hydrochloride
  • HY-14648A
    Dexamethasone acetate
    5+ Cited Publications

    Dexamethasone 21-acetate; Hexadecadrol acetate

    		 Glucocorticoid Receptor Inflammation/Immunology
    Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery .
    Dexamethasone acetate
  • HY-17417A
    Naloxone
    5+ Cited Publications

    		 Opioid Receptor Neurological Disease Cancer
    Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias .
    Naloxone
  • HY-103171
    BAY 60-6583
    Maximum Cited Publications
    7 Publications Verification

    		 Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50=3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
    BAY 60-6583
  • HY-N7922
    Urolithin M5
    1 Publications Verification

    Decarboxyellagic acid

    		 Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis Infection Neurological Disease
    Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC50 values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .
    Urolithin M5
  • HY-P990094
    Trabikibart

    CSL311

    		 c-Fms Inflammation/Immunology
    Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .
    Trabikibart
  • HY-N0412
    Sesamoside

    		PERK JNK TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    Sesamoside is an orally active anti-inflammatory, anti-hypoxic and analgesic agent. Sesamoside inhibits the phosphorylation of ERK and JNK, downregulates NLRP3 expression, restricts the nuclear localization of P65, regulates AKR1B1 expression, and reduces the expression of TRPV1 gene in the spinal cord. Sesamoside reduces the production of TNF-α, IL-6, IL-1β, iNOS and NO, restores cellular metabolism and organ function, and alleviates cold and mechanical hyperalgesia. Sesamoside can be used in research related to septic shock, high-altitude pulmonary edema and neuropathic pain .
    Sesamoside
  • HY-N6723
    Fumonisin B2

    		Ceramidase Acyltransferase Infection Cancer
    Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .
    Fumonisin B2
  • HY-48917
    C10 Bisphosphonate

    		Phospholipase Apoptosis Inflammation/Immunology
    C10 Bisphosphonate is an acid sphingomyelinase (aSMase) inhibitor with an IC50 of 0.02 μM in rats. C10 Bisphosphonate inhibits Dexamethasone (HY-14648)-induced cell apoptosis (apoptosis) and alleviates platelet-activating factor (PAF)-induced pulmonary edema. C10 Bisphosphonate can be used for the research of pulmonary edema .
    C10 Bisphosphonate
  • HY-11095
    NPS 2390

    		mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase Cardiovascular Disease Neurological Disease
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
    NPS 2390
  • HY-N14001
    Naamidine J

    		TNF Receptor Interleukin Related Arginase PD-1/PD-L1 Inflammation/Immunology Cancer
    Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors .
    Naamidine J
  • HY-14648AR
    Dexamethasone acetate (Standard)

    Dexamethasone 21-acetate (Standard); Hexadecadrol acetate (Standard)

    		 Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Dexamethasone acetate (Standard) (Dexamethasone 21-acetate (Standard)) is the analytical standard of Dexamethasone acetate (HY-14648A). This product is intended for research and analytical applications. Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery.
    Dexamethasone acetate (Standard)
  • HY-114457
    Phosphatidylinositol 4,5-bisphosphate

    L-alpha-Phosphatidylinositol-4,5-bisphosphate; (PtdIns)-(4,5)-P2

    		 Phospholipase Inflammation/Immunology
    Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate) is a plasma membrane lipid that is enriched in the cytoplasmic leaflet of the plasma membrane. Phosphatidylinositol 4,5-bisphosphate serves as a substrate for phospholipase C and class I PI3K, generating diacylglycerol, inositol (1,4,5)-trisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate. Phosphatidylinositol 4,5-bisphosphate contributes to lamellipodial protrusion, directional cell migration, focal adhesion lipid generation, and trafficking of the GABAA receptor. Phosphatidylinositol 4,5-bisphosphate can be used in research related to acute lung injury and pulmonary edema .
    Phosphatidylinositol 4,5-bisphosphate
  • HY-N9279
    Dehydromonocrotaline

    Monocrotaline pyrrole; MCTP; 3,8-Didehydromonocrotaline

    		 Endogenous Metabolite Cardiovascular Disease Cancer
    Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC50 of 62.06 μM and a Ki of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors .
    Dehydromonocrotaline
  • HY-176464
    GSK2220691

    		TRP Channel Inflammation/Immunology
    SK2220691 is a potent TRPV4 inhibitor. SK2220691 inhibits pulmonary edema induced by GSK1016790. SK2220691 inhibits HCl-induced increases in key factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF) .
    GSK2220691
  • HY-17417R
    Naloxone hydrochloride (Standard)

    		Reference Standards Opioid Receptor Neurological Disease Cancer
    Naloxone (hydrochloride) (Standard) is the analytical standard of Naloxone (hydrochloride). This product is intended for research and analytical applications. Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .
    Naloxone hydrochloride (Standard)
  • HY-N9508
    Perilla ketone

    		Cytochrome P450 Inflammation/Immunology
    Perilla ketone is a naturally occurring xenobiotic compound. Perilla ketone is activated by pulmonary P450 cytochrome enzymes in the lung, resulting in severe pulmonary damage and development of diffuse pulmonary edema .
    Perilla ketone
  • HY-17417AR
    Naloxone (Standard)

    		Opioid Receptor Reference Standards Neurological Disease Cancer
    Naloxone (Standard) is the analytical standard of Naloxone. This product is intended for research and analytical applications. Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias .
    Naloxone (Standard)
  • HY-16506
    Trimethaphan camsylate

    Ro 2-2222; Thiophanium derivatives

    		 Adrenergic Receptor Cardiovascular Disease Others
    Trimethaphan camsylate is an arterial blood pressure lowering agent that has been shown to reduce pulmonary venous pressure in experimental pulmonary edema.
    Trimethaphan camsylate
  • HY-N9508R
    Perilla ketone (Standard)

    		Cytochrome P450 Reference Standards Inflammation/Immunology
    Perilla ketone is a naturally occurring xenobiotic compound. Perilla ketone is activated by pulmonary P450 cytochrome enzymes in the lung, resulting in severe pulmonary damage and development of diffuse pulmonary edema .
    Perilla ketone (Standard)
  • HY-106929B
    Moxilubant hydrochloride

    CGS 25019C hydrochloride

    		 Leukotriene Receptor Inflammation/Immunology
    Moxilubant (CGS 25019C) hydrochloride is an orally active BLT1 antagonist. Moxilubant hydrochloride inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant hydrochloride blocks LTB4-induced neutrophil functions. Moxilubant hydrochloride inhibits ear edema and neutrophil infiltration in mice. Moxilubant hydrochloride can be used in research related to chronic obstructive pulmonary disease .
    Moxilubant hydrochloride
  • HY-106929
    Moxilubant
    1 Publications Verification

    CGS 25019C free base

    		 Leukotriene Receptor Inflammation/Immunology
    Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease .
    Moxilubant
  • HY-W701470
    W140 hydrobromide

    		LPL Receptor Inflammation/Immunology
    W140 hydrobromide is a S1P1 antagonist with the Ki of 2.84 μM, and can enhanceof capillary leakage and restoration of lymphocyte egress .
    W140 hydrobromide
  • HY-135487
    Sibenadet

    AR-C68397AA free base; AR-C68397XX

    		 Dopamine Receptor Adrenergic Receptor Neurological Disease
    Sibenadet (AR-C68397AA free base) is a dual dopamine D2/β2-adrenoceptor agonist with selective β2-adrenoceptor agonism. Sibenadet inhibits capsaicin-induced plasma protein extravasation in rat trachea. Sibenadet suppresses edema from sensory nerve fiber activation by activating β2-adrenoceptor. Sibenadet is promising for research of chronic obstructive pulmonary disease (COPD) .
    Sibenadet
  • HY-103171R
    BAY 60-6583 (Standard)

    		Reference Standards Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    BAY 60-6583 (Standard) is the analytical standard of BAY 60-6583. This product is intended for research and analytical applications. BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
    BAY 60-6583 (Standard)
  • HY-W744577
    Dexamethasone acetate-d5

    Dexamethasone 21-acetate-d5; Hexadecadrol acetate-d5

    		 Isotope-Labeled Compounds Glucocorticoid Receptor Inflammation/Immunology
    Dexamethasone acetate-d5 (Dexamethasone 21-acetate-d5; Hexadecadrol acetate-d5) is the deuterium labeled Dexamethasone acetate (HY-14648A). Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery.
    Dexamethasone acetate-d5
  • HY-183906
    GSK3491943

    		TRP Channel Cardiovascular Disease
    GSK3491943 is an antagonist of the transient receptor potential vanilloid subtype 4 (TRPV4) ion channel. GSK3491943 is applicable to research related to pulmonary edema induced by heart failure .
    GSK3491943
  • HY-184027
    IDO1/TDO-IN-12

    		Indoleamine 2,3-Dioxygenase (IDO) TNF Receptor Interleukin Related Inflammation/Immunology
    IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI) .
    IDO1/TDO-IN-12
  • HY-106929R
    Moxilubant (Standard)

    CGS 25019C free base (Standard)

    		 Leukotriene Receptor Reference Standards Inflammation/Immunology
    Moxilubant (CGS 25019C free base) Standard is the analytical standard of Moxilubant (HY-106929). This product is intended for research and analytical applications. Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease .
    Moxilubant (Standard)
  • HY-N19847
    LYRM03

    		Drug Derivative Aminopeptidase Endogenous Metabolite Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) NF-κB p38 MAPK IKK NO Synthase COX Inflammation/Immunology Cancer
    LYRM03 is a derivative of Ubenimex (HY-B0134) and a Aminopeptidase N inhibitor. LYRM03 is isolated from Streptomyces HCCB10043. LYRM03 inhibits TLR4, MyD88, NLRP3, ASC, NF-κB and p38 MAPK, stabilizes IκB, and suppresses LPS-induced expression of iNOS and COX-2. LYRM03 reduces the levels of inflammatory cytokines and oxidative stress markers, and alleviates pulmonary edema. LYRM03 exhibits anticancer activity against breast cancer. LYRM03 has anti-inflammatory activity. LYRM03 can be used in the research of acute lung injury and breast cancer .
    LYRM03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: